Clinical Trial Update: rhTNK-tPA Thrombolytic Removal of Intraventricular Hemorrhage [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating rhTNK-tPA as a thrombolytic to remove intraventricular hemorrhage is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intraventricular Hemorrhage

Drugs mentioned

• rhTNK-tPA (tenecteplase)

Snippet

Sponsor: Beijing Tiantan Hospital | Conditions: Intraventricular Hemorrhage | Phase 1 | Status: RECRUITING